https://orcid.org/0000-0001-9929-1909
References
- Hadley GR, Gayle JA, Ripoll J, et al. Post-herpetic neuralgia: a review. Curr Pain Headache Rep. 2016;20(3):17.
- Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Health. 2016;9:447–454. doi:10.2147/JMDH.S106340
- Bettinger JJ, Wegrzyn EL, Fudin J. Pain management in the elderly: focus on safe prescribing. Pract Pain Manag. 2017;17(3).
- Shrestha M, Chen A. Modalities in managing postherpetic neuralgia. Korean J Pain. 2018;31(4):235–243. doi:10.3344/kjp.2018.31.4.235
- Fornasari D. Pharmacotherapy for neuropathic pain: a review. Pain Ther. 2017;6(Suppl 1):25–33. doi:10.1007/s40122-017-0091-4
- Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014;7:125–132. doi:10.2147/JPR.S57242
- ZTLIDO® (Lidocaine Topical System): Prescribing Information. San Diego, California, USA: Scilex Pharmaceuticals; 2018.
- LIDODERM® (Lidocaine Patch 5%): Prescribing Information. Malvern, Pennsylvania, USA: Endo Pharmaceuticals; 2018.
- Lenz TL. The effects of high physical activity on pharmacokinetic drug interactions. Expert Opin Drug Metab Toxicol. 2011;7(3):257–266. doi:10.1517/17425255.2011.553190
- Vanakoski J, Seppala T. Heat exposure and drugs: a review of the effects of hyperthermia on pharmacokinetics. Clin Pharmacokinet. 1998;34(4):311–322. doi:10.2165/00003088-199834040-00004
- US Food and Drug Administration. Public health advisory: life-threatening side effects with the use of skin products containing numbing ingredients for cosmetic procedures [archive]. February 6, 2007 [ updated August 19, 2013]. Available from: https://wayback.archive-it.org/7993/20171105015424/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm054718.htm. Accessed May 8, 2020.
- Benowitz NJ, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet. 1978;3:177–201. doi:10.2165/00003088-197803030-00001
- Guidance for Industry. Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs. U.S. Department of Health and Human Services, Food and Drug Administration, ed. Rockville, MD, USA; 2018. Available from: https://www.fda.gov/media/117569/download. Accessed July 30, 2019.
- Food and Drug Administration. Assessing Adhesion with Transdermal and Topical Delivery Systems for ANDAs - Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, ed. Rockville, MD, USA; 2018. Available from: https://www.fda.gov/media/117569/download. Accessed July 30, 2019.
- Hao J, Ghosh P, Li SK, Newman B, Kasting GB, Raney SG. Heat effects on drug delivery across human skin. Expert Opin Drug Deliv. 2016;13(5):755–768. doi:10.1517/17425247.2016.1136286